amiodarone has been researched along with Hypotension in 45 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Hypotension: Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atrial fibrillation occurred in 15% of the patients receiving placebo and in 8% of the patients receiving verapamil (difference not significant)." | 9.08 | Verapamil as prophylactic treatment for atrial fibrillation after lung operations. ( Demedts, M; Demuynck, K; Deneffe, G; Lacquet, L; Tits, G; Tjandra-Maga, T; Van Mieghem, W, 1996) |
| "The identified trials were eligible for meta-analysis if they met the following criteria: patients had recent-onset atrial fibrillation; patients were randomized to intravenous amiodarone, placebo, or another antiarrhythmic agent; no other antiarrhythmic agent except digoxin was administered simultaneously with intravenous amiodarone or other active treatments; the number and percentage of conversions to sinus rhythm after treatment began were reported; and the number and type of adverse drug reactions occurring after treatment began were reported." | 8.81 | Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. ( Hilleman, DE; Spinler, SA, 2002) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 8.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| "The use of amiodarone for postoperative atrial fibrillation (AF) is widespread; however, there is a paucity of data on the optimal duration of overlap when transitioning from intravenous (IV) to oral amiodarone." | 8.12 | Intravenous to Oral Transition of Amiodarone (IOTA): Effect of Various Durations of Overlap on Atrial Fibrillation Recurrence After Cardiothoracic Surgery. ( Lam, JC; Lee, YG; Maurer, J; Patanwala, AE; Radosevich, JJ; Stevenson, B, 2022) |
| "Intravenous amiodarone can cause severe and refractory hypotension." | 7.81 | Amiodarone-Induced Life-Threatening Refractory Hypotension. ( Doshi, D; Jayawardana, R, 2015) |
| "We present a case of severe acute kidney injury (AKI) occurring shortly after the initiation of dronedarone therapy, which we suspect was the result of an adverse drug reaction." | 7.79 | Reversible acute kidney injury requiring haemodialysis five days after starting dronedarone in a stable 71-year-old man at risk of cardiovascular polypharmacy. ( Leaver, L; Maruthappu, M; Wayne, RP; Young, C, 2013) |
| "Eleven critically ill patients with life-threatening cardiac arrhythmias refractory to currently approved antiarrhythmic drugs were treated with intravenous amiodarone." | 7.67 | Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient. ( Leak, D, 1986) |
| "Hepatotoxicity due to intravenous amiodarone (HIVAD) is a rare side effect with a distinct pattern of enzyme disturbances compared to liver damage from oral amiodarone." | 5.37 | Acute amiodarone liver toxicity likely due to ischemic hepatitis. ( Fried, M; Gluck, N; Porat, R, 2011) |
| "The initial arrhythmia was 2/1 atrial flutter (n = 4), 1/1 atrial flutter (n = 2) and atrial fibrillation (n = 1)." | 5.31 | [Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis]. ( Aouate, P; Dubois-Randé, JL; Elbaz, N; Fontaine, G; Frank, R; Klug, D; Lacotte, J; Lelouche, D; Raguin, D; Tonet, J, 2002) |
| "Hypotension is the most frequent adverse event reported with intravenous amiodarone." | 5.11 | Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. ( Bailin, SJ; Borbola, J; Bridges, DE; Haffajee, CI; Kerin, NZ; Lakatos, F; Molnar, J; Paladino, WP; Sarosi, I; Somberg, JC; Tarjan, J; Timar, S, 2004) |
| "The duration, severity, and cause of hypotension after intravenous amiodarone has not been well characterized in anesthetized cardiac surgical patients." | 5.10 | Acute circulatory actions of intravenous amiodarone loading in cardiac surgical patients. ( Augoustides, JG; Cheung, AT; Gardner, TJ; Harrington, A; Levy, WJ; Savino, JS; Weiss, SJ, 2003) |
| "Atrial fibrillation occurred in 15% of the patients receiving placebo and in 8% of the patients receiving verapamil (difference not significant)." | 5.08 | Verapamil as prophylactic treatment for atrial fibrillation after lung operations. ( Demedts, M; Demuynck, K; Deneffe, G; Lacquet, L; Tits, G; Tjandra-Maga, T; Van Mieghem, W, 1996) |
| "The identified trials were eligible for meta-analysis if they met the following criteria: patients had recent-onset atrial fibrillation; patients were randomized to intravenous amiodarone, placebo, or another antiarrhythmic agent; no other antiarrhythmic agent except digoxin was administered simultaneously with intravenous amiodarone or other active treatments; the number and percentage of conversions to sinus rhythm after treatment began were reported; and the number and type of adverse drug reactions occurring after treatment began were reported." | 4.81 | Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. ( Hilleman, DE; Spinler, SA, 2002) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 4.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| "The use of amiodarone for postoperative atrial fibrillation (AF) is widespread; however, there is a paucity of data on the optimal duration of overlap when transitioning from intravenous (IV) to oral amiodarone." | 4.12 | Intravenous to Oral Transition of Amiodarone (IOTA): Effect of Various Durations of Overlap on Atrial Fibrillation Recurrence After Cardiothoracic Surgery. ( Lam, JC; Lee, YG; Maurer, J; Patanwala, AE; Radosevich, JJ; Stevenson, B, 2022) |
| "Intravenous amiodarone can cause severe and refractory hypotension." | 3.81 | Amiodarone-Induced Life-Threatening Refractory Hypotension. ( Doshi, D; Jayawardana, R, 2015) |
| "Two of the excipients in intravenous formulations of amiodarone, polysorbate 80 and benzyl alcohol, have been shown to cause hypotension." | 3.81 | Evaluation of the Hemodynamic Effects of Intravenous Amiodarone Formulations During the Maintenance Phase Infusion. ( Fleming, T; Heidel, E; Lindquist, DE; Rowe, AS; Yates, JR, 2015) |
| "We present a case of severe acute kidney injury (AKI) occurring shortly after the initiation of dronedarone therapy, which we suspect was the result of an adverse drug reaction." | 3.79 | Reversible acute kidney injury requiring haemodialysis five days after starting dronedarone in a stable 71-year-old man at risk of cardiovascular polypharmacy. ( Leaver, L; Maruthappu, M; Wayne, RP; Young, C, 2013) |
| " Hypotension frequently occurs with use of intravenous amiodarone and is managed by slowing the rate of administration." | 3.76 | The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period. ( Cooper, WD; Cushing, DJ; Gralinski, MR; Lipicky, RJ, 2010) |
| "Our objective is to investigate to what extent amiodarone is sequestered by intravenously administered lipid emulsion in plasma of pigs and whether the lipid emulsion inhibits amiodarone-induced hypotension." | 3.76 | Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs. ( Litonius, E; Neuvonen, PJ; Niiya, T; Petäjä, L; Rosenberg, PH, 2010) |
| " administration is systemic hypotension which has been attributed to the cosolvents used in the formulation, polysorbate 80 and benzyl alcohol." | 3.75 | PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. ( Cooper, WD; Cushing, DJ; Gralinski, MR; Kowey, PR; Lipicky, RJ; Massey, BW, 2009) |
| "This study was designed to test the hypothesis that rapid bolus administration of an aqueous formulation of intravenous amiodarone causes less hypotension than a 10-minute infusion of the standard formulation, Cordarone IV." | 3.72 | Comparative effects of rapid bolus administration of aqueous amiodarone versus 10-minute cordarone I.v. infusion on mean arterial blood pressure in conscious dogs. ( Cvetanovic, I; Molnar, J; Ranade, V; Somberg, JC, 2004) |
| "Eleven critically ill patients with life-threatening cardiac arrhythmias refractory to currently approved antiarrhythmic drugs were treated with intravenous amiodarone." | 3.67 | Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient. ( Leak, D, 1986) |
| " Thus, in these patients, the speed and dosing accuracy of an intravenous formulation would be beneficial." | 2.68 | Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. ( Cannom, DS; Chilson, DA; Friehling, T; Kopelman, HA; Kowey, PR; Levine, JH; Platia, EV; Scheinman, MM; Wilber, DJ, 1995) |
| " However, there was no clear dose-response relation observed in this trial with respect to success rates (primary end point), time to first recurrence of tachyarrhythmia (post hoc analysis) or mortality (secondary end point) over 24 h." | 2.68 | Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. ( Chilson, DA; Gomes, A; Levine, JH; Massumi, A; Platia, EV; Scheinman, MM; Winkle, RA; Woosley, RL, 1996) |
| "Hepatotoxicity due to intravenous amiodarone (HIVAD) is a rare side effect with a distinct pattern of enzyme disturbances compared to liver damage from oral amiodarone." | 1.37 | Acute amiodarone liver toxicity likely due to ischemic hepatitis. ( Fried, M; Gluck, N; Porat, R, 2011) |
| "On admission, 7 patients had a congestive heart failure and 3 of whom had cardiovascular collapse." | 1.36 | Intravenous amiodarone used alone or in combination with digoxin for life-threatening supraventricular tachyarrhythmia in neonates and small infants. ( Aslan, Y; Celiker, A; Dilber, B; Dilber, E; Gedik, Y; Mutlu, M, 2010) |
| "Procainamide was not more effective than amiodarone for the termination of sustained VT, but the ability to detect a significant difference was limited by the study design and potential confounding." | 1.36 | Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison. ( deSouza, IS; Ellinor, PT; Marill, KA; Nishijima, DK; Ruskin, JN; Senecal, EL; Setnik, GS; Stair, TO, 2010) |
| "Amiodarone is a potent anti-arrhythmic with a large pharmacological spectrum that shares the mechanisms of action of all classes of anti-arrhythmic drugs." | 1.33 | Acute cardiodepressant effects induced by bolus intravenous administration of amiodarone in rabbits. ( Lessa, MA; Tibiriçá, E, 2005) |
| "Sustained monomorphic ventricular tachycardia was defined as a tachycardia with uninterrupted duration or rapid recurrence despite automatic internal cardiac defibrillator therapy for at least 5 minutes before amiodarone treatment, monomorphic morphology, rate greater than 120 beats/min, QRS duration greater than 120 ms, and subsequently determined to be ventricular tachycardia by ECG criteria (eg, atrioventricular dissociation), implanted device interrogation, or formal electrophysiology study." | 1.33 | Amiodarone is poorly effective for the acute termination of ventricular tachycardia. ( deSouza, IS; Marill, KA; Nishijima, DK; Ruskin, JN; Setnik, GS; Stair, TO, 2006) |
| "We report a case of a patient with paroxysmal atrial fibrillation (PAF) and with a permanent AAIR (bipolar atrial-inhibited adaptive rate) pacemaker who suffered life-threatening episodes of arrhythmias during operation." | 1.33 | Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery. ( Borel, CO; Lin, JA; Wang, WB; Wong, CS; Wu, CT; Yang, CP; Yeh, CC, 2006) |
| "The initial arrhythmia was 2/1 atrial flutter (n = 4), 1/1 atrial flutter (n = 2) and atrial fibrillation (n = 1)." | 1.31 | [Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis]. ( Aouate, P; Dubois-Randé, JL; Elbaz, N; Fontaine, G; Frank, R; Klug, D; Lacotte, J; Lelouche, D; Raguin, D; Tonet, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (11.11) | 18.7374 |
| 1990's | 13 (28.89) | 18.2507 |
| 2000's | 15 (33.33) | 29.6817 |
| 2010's | 11 (24.44) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Lam, JC | 1 |
| Stevenson, B | 1 |
| Lee, YG | 1 |
| Maurer, J | 1 |
| Patanwala, AE | 1 |
| Radosevich, JJ | 1 |
| Maghrabi, K | 1 |
| Uzun, O | 1 |
| Kirsh, JA | 1 |
| Balaji, S | 1 |
| Von Bergen, NH | 1 |
| Sanatani, S | 1 |
| Young, C | 1 |
| Maruthappu, M | 1 |
| Wayne, RP | 1 |
| Leaver, L | 1 |
| Shah, R | 1 |
| Deam, AG | 1 |
| Doshi, D | 1 |
| Jayawardana, R | 1 |
| Lindquist, DE | 1 |
| Rowe, AS | 1 |
| Heidel, E | 1 |
| Fleming, T | 1 |
| Yates, JR | 1 |
| Cushing, DJ | 2 |
| Kowey, PR | 2 |
| Cooper, WD | 2 |
| Massey, BW | 1 |
| Gralinski, MR | 2 |
| Lipicky, RJ | 2 |
| Dilber, E | 1 |
| Mutlu, M | 1 |
| Dilber, B | 1 |
| Aslan, Y | 1 |
| Gedik, Y | 1 |
| Celiker, A | 1 |
| Marill, KA | 2 |
| deSouza, IS | 2 |
| Nishijima, DK | 2 |
| Senecal, EL | 1 |
| Setnik, GS | 2 |
| Stair, TO | 2 |
| Ruskin, JN | 2 |
| Ellinor, PT | 1 |
| Niiya, T | 1 |
| Litonius, E | 1 |
| Petäjä, L | 1 |
| Neuvonen, PJ | 1 |
| Rosenberg, PH | 1 |
| Gluck, N | 1 |
| Fried, M | 1 |
| Porat, R | 1 |
| Guglin, M | 1 |
| Dias Da Silva, VJ | 1 |
| Gnecchi-Ruscone, T | 1 |
| Lavelli, B | 1 |
| Bellina, V | 1 |
| Manzella, D | 1 |
| Porta, A | 1 |
| Malliani, A | 1 |
| Montano, N | 1 |
| Aouate, P | 1 |
| Elbaz, N | 1 |
| Klug, D | 1 |
| Lacotte, J | 1 |
| Raguin, D | 1 |
| Frank, R | 1 |
| Lelouche, D | 1 |
| Dubois-Randé, JL | 1 |
| Tonet, J | 1 |
| Fontaine, G | 1 |
| Cheung, AT | 1 |
| Weiss, SJ | 1 |
| Savino, JS | 1 |
| Levy, WJ | 1 |
| Augoustides, JG | 1 |
| Harrington, A | 1 |
| Gardner, TJ | 1 |
| MacFadyen, RJ | 1 |
| Palmer, TJ | 1 |
| Hisamuddin, K | 1 |
| Somberg, JC | 2 |
| Timar, S | 1 |
| Bailin, SJ | 1 |
| Lakatos, F | 1 |
| Haffajee, CI | 1 |
| Tarjan, J | 1 |
| Paladino, WP | 1 |
| Sarosi, I | 1 |
| Kerin, NZ | 1 |
| Borbola, J | 1 |
| Bridges, DE | 1 |
| Molnar, J | 2 |
| Canivet, JL | 1 |
| Yans, T | 1 |
| Roediger, L | 1 |
| Radermecker, MA | 1 |
| Cvetanovic, I | 1 |
| Ranade, V | 1 |
| Lessa, MA | 1 |
| Tibiriçá, E | 1 |
| Lin, JA | 1 |
| Borel, CO | 1 |
| Wang, WB | 1 |
| Wong, CS | 1 |
| Yeh, CC | 1 |
| Yang, CP | 1 |
| Wu, CT | 1 |
| Beall, JW | 1 |
| Mahan, EF | 1 |
| Blau, AB | 1 |
| Chockalingam, A | 1 |
| Tejwani, L | 1 |
| Aggarwal, K | 1 |
| Dellsperger, KC | 1 |
| Turner, S | 1 |
| Mathews, L | 1 |
| Pandharipande, P | 1 |
| Thompson, R | 1 |
| Buchser, E | 1 |
| Chiolero, R | 1 |
| Martin, P | 1 |
| Freeman, J | 1 |
| Scheinman, MM | 3 |
| Levine, JH | 2 |
| Cannom, DS | 1 |
| Friehling, T | 1 |
| Kopelman, HA | 1 |
| Chilson, DA | 2 |
| Platia, EV | 2 |
| Wilber, DJ | 1 |
| Lee, HS | 1 |
| Quinn, T | 1 |
| Boyle, RM | 1 |
| Massumi, A | 1 |
| Winkle, RA | 1 |
| Gomes, A | 1 |
| Woosley, RL | 1 |
| Van Mieghem, W | 1 |
| Tits, G | 1 |
| Demuynck, K | 1 |
| Lacquet, L | 1 |
| Deneffe, G | 1 |
| Tjandra-Maga, T | 1 |
| Demedts, M | 1 |
| Pethig, K | 1 |
| Wahlers, T | 1 |
| Tager, S | 1 |
| Borst, HG | 1 |
| Dick, W | 1 |
| Bossaert, L | 1 |
| Chamberlain, D | 1 |
| Porterfield, LM | 1 |
| Mets, B | 1 |
| Michler, RE | 1 |
| Delphin, ED | 1 |
| Oz, MC | 1 |
| Landry, DW | 1 |
| Maury, P | 1 |
| Vuille, C | 1 |
| Metzger, J | 1 |
| Veragut, B | 1 |
| Schoenenberger, I | 1 |
| Elamly, A | 1 |
| Chevrolet, JC | 1 |
| Hilleman, DE | 1 |
| Spinler, SA | 1 |
| Hohnloser, SH | 1 |
| Zabel, M | 1 |
| Zehender, M | 1 |
| Meinertz, T | 1 |
| Just, H | 1 |
| Mackay, JH | 1 |
| Walker, IA | 1 |
| Bethune, DW | 1 |
| Warren, R | 1 |
| Vohra, J | 1 |
| Hunt, D | 1 |
| Hamer, A | 1 |
| Geary, VM | 1 |
| Thaker, UN | 1 |
| Chalmers, PC | 1 |
| Sheikh, F | 1 |
| Helmy, I | 1 |
| Herre, JM | 1 |
| Gee, G | 1 |
| Sharkey, H | 1 |
| Malone, P | 1 |
| Sauve, MJ | 1 |
| Griffin, JC | 1 |
| Bolińska, H | 1 |
| Musiał, WJ | 1 |
| Ruta, J | 1 |
| Leak, D | 1 |
| Lee, TH | 1 |
| Friedman, PL | 1 |
| Goldman, L | 1 |
| Stone, PH | 1 |
| Antman, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for amiodarone and Hypotension
| Article | Year |
|---|---|
Dynamic left ventricular outflow tract obstruction in acute myocardial infarction with shock: cause, effect, and coincidence.
Topics: Adrenergic beta-Antagonists; Aged; Algorithms; Amiodarone; Cardiac Catheterization; Diagnosis, Diffe | 2007 |
[Severe flecainide acetate poisoning. Apropos of a case].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Biological Availability; Calcium Gluconate | 1999 |
Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cohort Studies; Humans; Hypote | 2002 |
Efficacy of intravenously administered amiodarone for short-term control of serious arrhythmias.
Topics: Action Potentials; Amiodarone; Arrhythmias, Cardiac; Electrophysiology; Hemodynamics; Humans; Hypote | 1992 |
5 trials available for amiodarone and Hypotension
| Article | Year |
|---|---|
Acute circulatory actions of intravenous amiodarone loading in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Blood Pressure Determination; Cardiac Output; Coronary A | 2003 |
Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Hypotension; Infusions, | 2004 |
Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; H | 1995 |
Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group.
Topics: Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Bradycardia; Cause of Death; Chi-Square Di | 1996 |
Verapamil as prophylactic treatment for atrial fibrillation after lung operations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Humans; Hypotension; Incidence | 1996 |
36 other studies available for amiodarone and Hypotension
| Article | Year |
|---|---|
Intravenous to Oral Transition of Amiodarone (IOTA): Effect of Various Durations of Overlap on Atrial Fibrillation Recurrence After Cardiothoracic Surgery.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Humans; | 2022 |
Cardiovascular Collapse with Intravenous Amiodarone in Children: A Multi-Center Retrospective Cohort Study.
Topics: Administration, Intravenous; Adolescent; Age Distribution; Amiodarone; Anti-Arrhythmia Agents; Blood | 2019 |
Reversible acute kidney injury requiring haemodialysis five days after starting dronedarone in a stable 71-year-old man at risk of cardiovascular polypharmacy.
Topics: Acute Kidney Injury; Aged; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Cardiovascul | 2013 |
Wide complex tachycardia in a patient with a family history of sudden death.
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden; Electrocardiography; Humans; Hypotension; Male; M | 2015 |
Amiodarone-Induced Life-Threatening Refractory Hypotension.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hypotension; Male | 2015 |
Evaluation of the Hemodynamic Effects of Intravenous Amiodarone Formulations During the Maintenance Phase Infusion.
Topics: Aged; Aged, 80 and over; Amiodarone; Antihypertensive Agents; Benzyl Alcohols; Cyclodextrins; Dosage | 2015 |
PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Benzyl Alcohol; beta-Cyclodextrins; Blood Pressure; Car | 2009 |
The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period.
Topics: Amiodarone; Animals; Blood Pressure; Dogs; Female; Heart Rate; Hypotension; Infusions, Intravenous; | 2010 |
Intravenous amiodarone used alone or in combination with digoxin for life-threatening supraventricular tachyarrhythmia in neonates and small infants.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Drug Evaluation; Drug Therap | 2010 |
Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cohort Studies; Drug Administration Schedule; Electrocardi | 2010 |
Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs.
Topics: Amiodarone; Animals; Blood Pressure; Fat Emulsions, Intravenous; Female; Heart Rate; Hypotension; Ma | 2010 |
Acute amiodarone liver toxicity likely due to ischemic hepatitis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Biopsy; Chemical and Drug Induced Liver Injury; Female; He | 2011 |
Occam's razor and ischemic hepatitis.
Topics: Amiodarone; Chemical and Drug Induced Liver Injury; Female; Hepatitis; Humans; Hypotension; Ischemia | 2012 |
Opposite effects of iv amiodarone on cardiovascular vagal and sympathetic efferent activities in rats.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atropine; Autonomic Fibers, Preganglionic; Baroreflex; | 2002 |
[Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial | 2002 |
Rapidly fatal acute amiodarone hepatitis occurring in the context of multiple organ failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Dilated; Chemical and Drug | 2003 |
Left atrial thrombus formation early after mitral valve replacement.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiac Output, Low; Echoca | 2004 |
Comparative effects of rapid bolus administration of aqueous amiodarone versus 10-minute cordarone I.v. infusion on mean arterial blood pressure in conscious dogs.
Topics: Amiodarone; Animals; Blood Pressure; Chemistry, Pharmaceutical; Dogs; Female; Hypotension; Infusions | 2004 |
Acute cardiodepressant effects induced by bolus intravenous administration of amiodarone in rabbits.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiac Output; Female; Hypotension; In | 2005 |
Amiodarone is poorly effective for the acute termination of ventricular tachycardia.
Topics: Aged; Aged, 80 and over; Amiodarone; Combined Modality Therapy; Dose-Response Relationship, Drug; El | 2006 |
Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery.
Topics: Aged; Amiodarone; Anesthesia, General; Anti-Arrhythmia Agents; Atrial Fibrillation; Atropine; Bradyc | 2006 |
Use of amiodarone in a patient with a shellfish allergy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Follow-Up Studies; Food Hypersensitiv | 2007 |
Dolasetron-induced torsades de pointes.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Antiemetics; Cardiopulmonary Resusc | 2007 |
Amiodarone-induced haemodynamic complications during anaesthesia.
Topics: Aged; Amiodarone; Benzofurans; Bradycardia; Female; Humans; Hypotension; Intraoperative Complication | 1983 |
Safety of thrombolytic treatment in patients with central venous cannulation.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Catheterization, Central Venous; Contraindications; Fema | 1995 |
Perioperative complications in combined aortic valve replacement and extraanatomic ascending-descending bypass.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aorta; Aorta, Thoracic; Aortic Coarctation; Aortic Valve; Aortic | 1996 |
European guidelines on resuscitation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Europe; Humans; Hypotension; Practice Guidelines as Topic; Resus | 1996 |
This drug needs close monitoring.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Drug Monitoring; Humans; Hypotension; Male; Nursing Assess | 1996 |
Refractory vasodilation after cardiopulmonary bypass for heart transplantation in recipients on combined amiodarone and angiotensin-converting enzyme inhibitor therapy: a role for vasopressin administration.
Topics: Aged; Aged, 80 and over; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardi | 1998 |
Amiodarone and anaesthesia: concurrent therapy with ACE inhibitors--an additional cause for concern?
Topics: Adult; Amiodarone; Anesthesia, Intravenous; Enalapril; Fentanyl; Humans; Hypotension; Male; Midazola | 1991 |
Serious interactions of sotalol with amiodarone and flecainide.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Drug Administration Schedule; Drug Interactions; Drug Therap | 1990 |
The use of angiotensin II to treat profound hypotension in a patient taking amiodarone.
Topics: Amiodarone; Angiotensin II; Blood Pressure; Cardiac Output; Cardiopulmonary Bypass; Humans; Hypotens | 1990 |
Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias.
Topics: Amiodarone; Arrhythmias, Cardiac; Bradycardia; Cardiac Pacing, Artificial; Electrocardiography; Emer | 1988 |
[Complications after oral and intravenous administration of amiodarone (cordaron)].
Topics: Administration, Oral; Adolescent; Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Female; Humans; Hyp | 1986 |
Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Blood Pressure; Dopamine; Electrocardiog | 1986 |
Sinus arrest and hypotension with combined amiodarone-diltiazem therapy.
Topics: Amiodarone; Benzazepines; Benzofurans; Diltiazem; Drug Interactions; Drug Therapy, Combination; Fema | 1985 |